http://www.laboratorytalk.com/news/fro/fro000.html Frost and Sullivan news releases on Laboratorytalk en-gb Copyright (C)2008 Pro-Talk Ltd. All rights reserved. Tue, 14 Oct 2008 08:00:00 UT Tue, 14 Oct 2008 08:00:00 UT http://www.pro-talk.com/images/protalklogo90.gif http://www.pro-talk.com/ 90 79 Increased funding and developing regulatory framework provide impetus to stem cell therapeutics market Fri, 23 Feb 2007 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro242.html Frost and Sullivan presented 12 awards at its 2006 Excellence in Chemicals awards banquet held in London this week Thu, 14 Dec 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro241.html Frost and Sullivan will host its annual Excellence in Chemicals awards banquet on Tuesday 12 December 2006, at the Le Meridien Piccadilly Hotel in London Thu, 07 Dec 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro239.html Innovative, non-invasive methods to deliver insulin are poised to transform diabetes management, according to this market anaylst's report Thu, 10 Aug 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro238.html Heightened awareness and knowledge about diabetes are boosting the acceptance of insulin therapy among people with type 2 diabetes Fri, 28 Jul 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro237.html Outstanding performances in Europe's healthcare industry were recognised at Frost and Sullivan's 2006 Excellence in Healthcare Awards Banquet held in London on 12 July 2006 Fri, 14 Jul 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro236.html With pharma companies experiencing weak R+D pipelines and biotechnology companies grappling with funding shortfalls, strategic alliances are being wielded as a tool for survival Tue, 13 Jun 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro235.html Frost and Sullivan valued the total European phytosterols market to be worth $184.6 million in 2005, and estimates this to reach $395.2 million in 2012 Wed, 31 May 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro234.html Increasing interest in the benefits of nutraceuticals are driving their use, and government policies aimed at liberalising previous restrictions on health food sales is helping to boost demand Tue, 30 May 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro233.html Neurological disorders and high level of unmet clinical need are to create opportunities in European central nervous system therapeutics market, says this analyst's report Mon, 29 May 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro232.html Greater emphasis on health and technological advances to boost uptake of amino acids in Europe, says this analyst's market report Thu, 25 May 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro231.html A steep decline in innovation levels, combined with the threat from generics and drug recalls is causing concern to several pharmaceutical companies Thu, 11 May 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro230.html Increased R+D funding from governments that have recognised the immense potential of stem cell applications in medical treatments and from venture capital firms are supporting this nascent market Wed, 12 Apr 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro229.html Analysis from Frost and Sullivan, Strategic Analysis of the Nutraceuticals Market in Southeast Asia, reveals that revenue in this industry totalled US$2,304.7 million in 2005 Tue, 11 Apr 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro228.html Some of the major vaccines anticipated to be introduced in the next five years include MMR + varicella, herpes zoster, rotavirus, human papilomavirus vaccines (HPV) and meningococcal infections Wed, 05 Apr 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro227.html Developers of assays for in-vitro diagnostics need to overcome the significant challenge of proving the worth of their technologies, to ease potential scepticism about the reliability of new assays Tue, 04 Apr 2006 08:00:00 UT Frost and Sullivan http://www.laboratorytalk.com/news/fro/fro226.html